What is the appropriate work‑up and management for an elderly patient with Waldenström macroglobulinemia on venetoclax (Venclexta) who has experienced progressive diffuse body aches and muscle spasms for eight months?

Workup and Management of Progressive Body Aches and Muscle Spasms in WM Patient on Venetoclax

This patient requires immediate evaluation for venetoclax-induced tumor lysis syndrome (TLS), IgM-related complications including hyperviscosity and neuropathy, and disease progression, with urgent laboratory assessment of electrolytes, uric acid, phosphate, calcium, LDH, serum IgM level, and serum viscosity. 1

Immediate Laboratory Workup

Critical TLS Assessment

• Measure serum electrolytes, uric acid, phosphate, calcium, creatinine, and LDH immediately to rule out laboratory or clinical TLS, which occurred in 7% of venetoclax-treated WM patients (4% with clinical TLS requiring intervention). 1
• Laboratory TLS can manifest with muscle spasms, weakness, and diffuse body aches due to electrolyte derangements. 1

IgM-Related Complications

• Check serum IgM level urgently; values >4000 mg/dL mandate prophylactic plasmapheresis before any treatment modification. 2
• Assess serum viscosity because symptomatic hyperviscosity constitutes a medical emergency requiring immediate plasmapheresis and can present with diffuse symptoms including muscle weakness. 2
• Test for cryoglobulins and cold agglutinins, as these IgM-mediated complications can cause musculoskeletal symptoms and require specific management. 2

Neuropathy Evaluation

• Evaluate for anti-myelin-associated glycoprotein (anti-MAG), antiganglioside M1, and anti-sulfatide IgM antibodies to diagnose IgM-related neuropathy, which commonly causes body aches and muscle symptoms in WM. 3
• WM patients commonly have baseline neuropathy from disease or prior treatment, particularly if previously exposed to bortezomib. 4

Disease Status Assessment

• Obtain complete blood count with differential to assess for cytopenias indicating disease progression or bone marrow compromise. 3, 2
• Measure beta-2 microglobulin and LDH as markers of disease activity and tumor burden. 5
• Perform bone marrow biopsy with flow cytometry if laboratory findings suggest disease progression, as venetoclax response may not always correlate with IgM levels. 3

Management Algorithm Based on Findings

If TLS is Present

• Immediately hold venetoclax and initiate aggressive hydration, allopurinol or rasburicase, and electrolyte correction. 1
• Venetoclax dose interruptions and/or reductions occurred in 41% of patients in the largest retrospective series. 1
• Consider permanent discontinuation if clinical TLS develops. 1

If Hyperviscosity is Confirmed

• Initiate plasmapheresis immediately as a temporizing measure; this is a medical emergency. 2
• Do not postpone treatment while awaiting additional workup when hyperviscosity is suspected. 2
• Definitive WM-directed cytoreductive therapy must follow without delay after plasmapheresis. 2

If IgM-Related Neuropathy is Diagnosed

• Continue venetoclax if tolerated, as it does not cause peripheral neuropathy unlike bortezomib, thalidomide, or vincristine. 3
• Avoid switching to bortezomib-based regimens where peripheral neuropathy is present, as this will exacerbate symptoms. 3
• Consider adding rituximab to venetoclax, as single-agent rituximab is appropriate for patients with IgM-related neuropathy. 3

If Disease Progression is Documented

• Venetoclax achieved a median PFS of 28.5 months in heavily pretreated patients, so progression at 8 months of therapy is concerning. 1
• Prior BTK inhibitor exposure (present in 82% of the venetoclax cohort) was the only factor associated with worse PFS in multivariate analysis. 1
• Consider switching to an alternative regimen: zanubrutinib (preferred first-line per Mayo Clinic), rituximab-bendamustine, or bortezomib-rituximab-dexamethasone depending on prior exposures. 5, 6

If Workup is Negative for Above Causes

• Obtain echocardiogram and BNP/NT-proBNP to rule out cardiac amyloidosis, a recognized cause of diffuse symptoms in WM. 2
• Check for herpes zoster reactivation, as WM patients on venetoclax face elevated risk due to immunosuppression, and post-herpetic neuralgia can cause prolonged body aches. 4
• Consider neurologist consultation for complex neuropathy cases that remain unexplained. 4

Common Pitfalls to Avoid

• Do not attribute symptoms solely to "treatment side effects" without ruling out TLS, which can be life-threatening. 1
• Do not continue venetoclax at full dose if laboratory TLS is present, even if asymptomatic; dose reduction or interruption is required. 1
• Do not overlook IgM-related complications simply because the patient is on active therapy; venetoclax may not rapidly reduce IgM in all patients. 3
• Do not switch to neurotoxic agents (bortezomib, thalidomide, vincristine) if neuropathy is confirmed, as this will worsen symptoms. 3